Evidence map›Paper›PMID 37080489›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2023

Sustained release hydrogel for durable locoregional chemoimmunotherapy for BRAF-mutated melanoma.

Jihoon Kim, Paul A Archer, Margaret P Manspeaker, Alexa R C Avecilla, Brian P Pollack, Susan N Thomas

Erratum issuedOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Role of pyroptosis in melanoma: Molecular mechanisms and therapeutic potentials.Apoptosis : an international journal on programmed cell death · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Jihoon KimParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA; Division of Biological Science and Technology, Yonsei University, Wonju 26493, South Korea.
Paul A ArcherParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, United States.
Margaret P ManspeakerParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA; School of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, GA 30332, United States.
Alexa R C AvecillaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Dr NW, Atlanta, Georgia 30332, USA and Emory University, 201 Dowman Drive, Atlanta, GA 30322, USA.
Brian P PollackWinship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road NE, Atlanta, GA 30322, USA; Departments of Dermatology and Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Susan N ThomasParker H. Petit Institute for Bioengineering and Bioscience, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA; Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology, 313 Ferst Dr NW, Atlanta, Georgia 30332, USA and Emory University, 201 Dowman Drive, Atlanta, GA 30322, USA; Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road NE, Atlanta, GA 30322, USA; George W. Woodruff School of Mechanical Engineering, Georgia Institute of Technology, 315 Ferst Dr NW, Atlanta, GA 30332, USA. Electronic address: susan.thomas@gatech.edu.
Georgia Institute of Technology · USEmory University · US

Funding

Lymph node-targeted multistage chemoimmunotherapy for lymphomaR01CA247484 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI FINN, M.G., THOMAS, SUSAN NAPIER · 2020 to 2024
$2.6M
Melanoma immunotherapy targeting sentinel lymph nodesR01CA207619 · NCI · GEORGIA INSTITUTE OF TECHNOLOGY · PI THOMAS, SUSAN NAPIER · 2016 to 2020
$2.0M
IVIS Spectrum in vivo Imaging SystemS10OD016264 · OD · GEORGIA INSTITUTE OF TECHNOLOGY · PI GARCIA, ANDRES J · 2015 to 2015
$595k
Role of HIV-1 Tat in the activation of HERV-K and development of HIV-1-lymphomaF31CA150523 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GONZALEZ-HERNANDEZ, MARTA JEANNETTE · 2010 to 2011
$65k
NCI NIH HHS F31 CA150523NCI NIH HHS R01 CA207619NCI NIH HHS R01 CA247484NIH HHS S10 OD016264
6 · The paper itself

Abstract

The wide prevalence of BRAF mutations in diagnosed melanomas drove the clinical advancement of BRAF inhibitors in combination with immune checkpoint blockade for treatment of advanced disease. However, deficits in therapeutic potencies and safety profiles motivate the development of more effective strategies that improve the combination therapy's therapeutic index. Herein, we demonstrate the benefits of a locoregional chemoimmunotherapy delivery system, a novel thermosensitive hydrogel comprised of gelatin and Pluronic® F127 components already widely used in humans in both commercial and clinical products, for the co-delivery of a small molecule BRAF inhibitor with immune checkpoint blockade antibody for the treatment of BRAF-mutated melanoma. In vivo evaluation of administration route and immune checkpoint target effects revealed intratumoral administration of antagonistic programmed cell death protein 1 antibody (aPD-1) lead to potent antitumor therapy in combination with BRAF inhibitor vemurafenib. The thermosensitive F127-g-Gelatin hydrogel that was evaluated in multiple murine models of BRAF-mutated melanoma that facilitated prolonged local drug release within the tumor (>1 week) substantially improved local immunomodulation, tumor control, rates of tumor response, and animal survival. Thermosensitive F127-g-Gelatin hydrogels thus improve upon the clinical benefits of vemurafenib and aPD-1 in a locoregional chemoimmunotherapy approach for the treatment of BRAF-mutated melanoma.

Indexed as

MelanomaProto-Oncogene Proteins B-rafAnimalsDelayed-Action PreparationsGelatinHumansHydrogelsImmune Checkpoint InhibitorsMiceMutationPolyethylenesPolypropylenesProtein Kinase InhibitorsVemurafenibBRAF protein, humanDelayed-Action PreparationsGelatinHydrogelsImmune Checkpoint InhibitorsPolyethylenesPolypropylenesProtein Kinase InhibitorsProto-Oncogene Proteins B-rafUCON 50-HB-5100VemurafenibBRAF inhibitorDrug delivery systemImmune checkpoint blockadeSustained releaseThermosensitive hydrogel

Identifiers

PMID37080489
PMCPMC10328138
OpenAlexW4366601917

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.